Clinical Trial Update: Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ADS-5102 for dyskinesia in Parkinson's disease patients treated with levodopa has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskinesia
• Levodopa-induced Dyskinesia
• Parkinson Disease

Drugs mentioned

• ADS-5102 (amantadine)

Snippet

Sponsor: Adamas Pharmaceuticals, Inc. | Conditions: Dyskinesia, Levodopa-Induced Dyskinesia (LID) | Phase 3 | Status: COMPLETED | Results posted: 2018-01-10